Change in IgG and evolution of lung function in children with cystic fibrosis

被引:25
作者
Proesmans, M. [1 ]
Els, C. [2 ]
Vermeulen, F. [1 ]
De Boeck, K. [1 ]
机构
[1] Univ Hosp Leuven, Dept Pediat, B-3000 Leuven, Belgium
[2] Univ Pretoria, Dept Pediat, ZA-0002 Pretoria, South Africa
关键词
IMMUNOGLOBULIN; DISEASE;
D O I
10.1016/j.jcf.2010.12.004
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Reports from the seventies and eighties have shown that cystic fibrosis (CF) patients with severe lung disease have high levels of IgG and that this is associated with worse prognosis. We decided to explore IgG level as a possible outcome parameter for lung disease severity in a cohort of pediatric CF patients treated according to current standards of care. Seventy three CF children older than 5 years (and max 15 years old at the initial evaluation) attending the same CF center were followed during a period of 4 years. Data collection included spirometry, height, weight, sputum cultures and total IgG. Median age at the start was 10 years. IgG z scores < 2 SD were seen in 2.7% of patients in 2004 and 2008. Twelve patients (16%) had an IgG > 2 SD in 2004 and this number increased to 18 (25%) in 2008. IgG z-scores were inversely correlated with FEV(1)% predicted (r=-0.323 in 2004; p <.001). In longitudinal evaluation, changes in IgG z-score correlate inversely with changes in FEV(1)% predicted (r=-0.498; p <.001). We can conclude that even for CF patients treated according to current standards IgG z-score increases with age and is correlated with a decline in FEV(1). (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:128 / 131
页数:4
相关论文
共 16 条
  • [1] Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO
  • [2] 2-L
  • [3] Doring Gerd, 2004, J Cyst Fibros, V3, P67, DOI 10.1016/j.jcf.2004.03.008
  • [4] Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic
    Garside, JP
    Kerrin, DP
    Brownlee, KG
    Gooi, HC
    Taylor, JM
    Conway, SP
    [J]. PEDIATRIC PULMONOLOGY, 2005, 39 (02) : 135 - 140
  • [5] Pathophysiology and management of pulmonary infections in cystic fibrosis
    Gibson, RL
    Burns, JL
    Ramsey, BW
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (08) : 918 - 951
  • [6] Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus
    Heijerman, Harry
    Westerman, Elsbeth
    Conway, Steven
    Touw, Daan
    Doring, Gerd
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (05) : 295 - 315
  • [7] HODSON ME, 1988, EUR RESPIR J, V1, P701
  • [8] Lee Tim W R, 2003, J Cyst Fibros, V2, P29, DOI 10.1016/S1569-1993(02)00141-8
  • [9] HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH CYSTIC-FIBROSIS
    MATTHEWS, WJ
    WILLIAMS, M
    OLIPHINT, B
    COLTEN, HR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (05) : 245 - 249
  • [10] Association between pulmonary function and sputum biomarkers in cystic fibrosis
    Mayer-Hamblett, Nicole
    Aitken, Moira L.
    Accurso, Frank J.
    Kronmal, Richard A.
    Konstan, Michael W.
    Burns, Jane L.
    Sagel, Scott D.
    Ramsey, Bonnie W.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (08) : 822 - 828